|
|
5-day change | 1st Jan Change | ||
|
172.74 USD |
+6.72% | +2.49% | +14.14% | |
April 22, 2025 at 02:42 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Barclays Raises Quest Diagnostics’ Price Target to $185 From $175 |
02:42pm |
MT |
|
Evercore ISI Adjusts Quest Diagnostics Price Target to $180 From $175 |
01:55pm |
MT |
|
Leerink Adjusts Price Target on Quest Diagnostics to $189 From $184 |
12:10pm |
MT |
|
Sector Update: Health Care Stocks Rise Pre-Bell Tuesday |
09:23am |
MT |
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Focus on Earnings Reports |
08:32am |
MT |
|
Quest Diagnostics Incorporated, Q1 2025 Earnings Call, Apr 22, 2025 |
08:30am |
|
|
Quest beats quarterly profit estimates on strong demand for diagnostic tests |
07:36am |
RE |
|
Quest Diagnostics Q1 Adjusted Earnings, Revenue Increase; 2025 Adjusted Earnings Outlook Affirmed |
07:08am |
MT |
|
(DGX) Quest Diagnostics Expects 2025 Net Revenue Range $10.70B – $10.85B, vs. FactSet Est of $10.78B |
06:55am |
MT |
|
(DGX) Quest Diagnostics Expects Full Year 2025 Adjusted EPS Range $9.55 – $9.80, vs. FactSet Est of $9.68 |
06:55am |
MT |
|
Earnings Flash (DGX) Quest Diagnostics Reports Q1 Revenue $2.65B, vs. FactSet Est of $2.63B |
06:55am |
MT |
|
Earnings Flash (DGX) Quest Diagnostics Posts Q1 Adjusted EPS $2.21, vs. FactSet Est of $2.15 |
06:55am |
MT |
|
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 |
06:45am |
CI |
|
Quest Diagnostics Launches New AD- Detect Blood Test to Aid in Confirming Alzheimer’s Disease |
Apr. 09 |
CI |
|
Quest Diagnostics- Introduces Hpv Specimen Self-Collection For Cervical Cancer Screening |
Apr. 02 |
RE |
|
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening |
Apr. 02 |
CI |
|
Redburn Atlantic Initiates Quest Diagnostics at Buy With $195 Price Target |
Apr. 02 |
MT |
|
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target |
Mar. 27 |
MT |
|
Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating |
Mar. 20 |
MT |
|
Quest Diagnostics Incorporated – Analyst/Investor Day |
Mar. 19 |
|
|
Quest Diagnostics Lowers Q1 Outlook, Reaffirms 2025 Guidance |
Mar. 19 |
MT |
|
Quest Diagnostics Incorporated Provides Earnings Guidance for the First Quarter of 2025 and Reaffirms Earnings Guidance for the Year 2025 |
Mar. 19 |
CI |
|
Quest Diagnostics Announces to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI |
Mar. 18 |
CI |
|
Baird Adjusts Price Target on Quest Diagnostics to $190 From $189, Maintains Outperform Rating |
Mar. 17 |
MT |
|
Quest Diagnostics Incorporated : Your health comes first |
Mar. 04 |
 |
DGX: Dynamic Chart
Quest Diagnostics Incorporated is the world’s leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
– testing and diagnostic services (97%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
– other (3%).
More about the company
Buy
Last Close Price
161.86USD
Average target price
179.27USD
Spread / Average Target
+10.75%
Consensus
